Biofrontera, Inc. (BFRI)
1.53
-0.03
(-1.92%)
USD |
NASDAQ |
Sep 09, 16:00
1.54
+0.01
(+0.65%)
After-Hours: 16:26
Biofrontera Gross Profit Margin (Quarterly) : 91.59% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 91.59% |
| March 31, 2026 | 90.92% |
| December 31, 2025 | 94.91% |
| September 30, 2025 | 70.44% |
| June 30, 2025 | 70.45% |
| March 31, 2025 | 61.61% |
| December 31, 2024 | 57.75% |
| September 30, 2024 | 44.67% |
| June 30, 2024 | 43.22% |
| March 31, 2024 | 46.63% |
| December 31, 2023 | 46.56% |
| September 30, 2023 | 45.58% |
| June 30, 2023 | 48.46% |
| Date | Value |
|---|---|
| March 31, 2023 | 45.89% |
| December 31, 2022 | 40.52% |
| September 30, 2022 | 45.49% |
| June 30, 2022 | 39.74% |
| March 31, 2022 | 45.84% |
| December 31, 2021 | 46.51% |
| September 30, 2021 | 44.07% |
| June 30, 2021 | 44.58% |
| March 31, 2021 | 42.90% |
| September 30, 2020 | 64.51% |
| June 30, 2020 | 42.42% |
| March 31, 2020 | 45.32% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -208.6% |
| Return on Assets | -28.17% |
| Return on Invested Capital | -68.36% |
| Profit Margin (Quarterly) | -5.03% |
| Operating Margin (Quarterly) | 7.30% |
| Return on Net Operating Assets | -52.83% |